Clinical trial · Interventional
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
Comparison of Plerixafor and G-CSF Versus G-CSF Alone for Stem Cell Mobilization in Patients With Multiple Myeloma Previously Treated With Lenalidomide
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow Accrual
Summary
Brief summary (as posted)
This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide. Giving colony-stimulating factors, such as G-CSF, and plerixafor helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory Multiple Myeloma | Multiple Myeloma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| filgrastim | Biological | Filgrastim | ALIAS |
| plerixafor | Drug | Plerixafor | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm I
- description
- Patients receive G-CSF SC QD on days 1-4.
- interventionNames
- Biological: filgrastim
- type
- EXPERIMENTAL
- label
- Arm II
- description
- Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
- interventionNames
- Drug: plerixafor
- Biological: filgrastim
Primary outcomes (1)
- measure
- Ability to Reach Target Collection of 5 x 10^6 CD34+ Cells/kg
- timeFrame
- In =< 2 days of leukaphereses
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of MM by International Myeloma Working Group Criteria * In first or second complete or partial remission or stable refractory but not actively progressing myeloma according to the classifications provided by The Center for International Blood \& Marrow Transplant Research * Received at least 2 cycles of lenalidomide therapy * Patients with MM scheduled to undergo stem cell harvest for possible allogeneic stem cell transplant (ASCT) * At least 2 weeks since last exposure to lenalidomide * Eastern Cooperative Oncology Group performance status of 0 or 1 * Prior to the start of mobilization: * white blood cell count \>/= 2.5 x 10\^9/L * absolute neutrophil count \>/= 1.2 x 10\^9/L * platelet count \>/=100 x 10\^9/L * creatinine clearance \>/= 30mL/minute * If childbearing potential, must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization; female patients will undergo pregnancy test prior to stem cell mobilization therapy Exclusion Criteria: * Had prior autologous or allogeneic transplantation * Received pegfilgrastim within 3 weeks or G-CSF within 14 days of first dose of G-CSF for mobilization * Failed previous hematopoietic stem cell collections or collection attempts * Received radiation therapy to the pelvic area * Received lenalidomide within 2 weeks of first dose of G-CSF for mobilization * Had received experimental therapy within 4 weeks of enrolling in study * Current or prior history of other malignancies, excluding basal cell carcinoma of the skin
References
Publications (0)
Data not yet available